

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

RD-ES

RRID:CVCL_2169

Type: Cell Line

Proper Citation

RRID:CVCL_2169

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2169

Proper Citation: RRID:CVCL_2169

Description: Cell line RD-ES is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Ewing sarcoma

Defining Citation: [PMID:8040301](#), [PMID:8221663](#), [PMID:8378080](#), [PMID:9738976](#), [PMID:11423975](#), [PMID:18082704](#), [PMID:18160777](#), [PMID:19787792](#), [PMID:20215515](#), [PMID:21822310](#), [PMID:22142829](#), [PMID:22460905](#), [PMID:25010205](#), [PMID:25223734](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:26428435](#), [PMID:28196595](#), [PMID:29464090](#), [PMID:30879952](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:36476851](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RD-ES

Synonyms: RDES, RDES-1

Cross References: BTO:BTO_0004202, CLO:CLO_0008774, EFO:EFO_0002316, CLDB:cl4128, CLDB:cl4129, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:HTB-166, BCRJ:0267, BioGRID_ORCS_Cell_line:194, BioSample:SAMN03470929, BioSample:SAMN10987904, cancercellines:CVCL_2169, Cell_Model_Passport:SIDM01316, CLS:300410, Cosmic:759890, Cosmic:1078386,

Cosmic:1082506, Cosmic:1085906, Cosmic:1381107, Cosmic:1718429, Cosmic:2228230, Cosmic:2250477, Cosmic:2294586, DepMap:ACH-000041, DSMZ:ACC-260, DSMZCellDive:ACC-260, GDSC:1330996, GEO:GSM393042, GEO:GSM510006, GEO:GSM887527, GEO:GSM888609, GEO:GSM1676310, GEO:GSM1701644, GEO:GSM5359730, GEO:GSM5359731, GEO:GSM5359732, GEO:GSM5359733, GEO:GSM5359734, GEO:GSM5359735, GEO:GSM5362971, GEO:GSM5362972, GEO:GSM5362973, GEO:GSM5362974, GEO:GSM5362975, GEO:GSM5362976, GEO:GSM5363991, GEO:GSM5363992, GEO:GSM5363993, GEO:GSM5363994, GEO:GSM5363995, IARC_TP53:1272, IARC_TP53:8400, IGRhCellID:RDES, LiGeA:CCLE_906, LINCS_LDP:LCL-1455, Pharmacodb:RDES_1297_2019, Progenetix:CVCL_2169, Wikidata:Q54949536

ID: CVCL_2169

Record Creation Time: 20220427T221454+0000

Record Last Update: 20260815T235624+0000

Ratings and Alerts

No rating or validation information has been found for RD-ES.

No alerts have been found for RD-ES.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Manara MC, et al. (2024) Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. *Cancer immunology research*, 12(2), 247.

Mancarella C, et al. (2023) Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. *Cancer gene therapy*, 30(9), 1285.

Martin JC, et al. (2022) WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. *Cancer research communications*, 2(6), 471.

Golinelli G, et al. (2022) Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma. *Translational oncology*, 15(1), 101240.

Palve V, et al. (2022) The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. *Cell chemical biology*, 29(2), 202.

Orth MF, et al. (2022) Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. *Cell reports*, 41(10), 111761.

Dirks WG, et al. (2021) Cross-contamination meets misclassification: Awakening of CHP-100 from sleeping beauty sleep-A reviewed model for Ewing's sarcoma. *International journal of cancer*.

Mercatelli N, et al. (2020) Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC. *Cancer letters*, 469, 111.

Yeung C, et al. (2019) Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. *Cancer research*, 79(19), 5060.

Srivastava S, et al. (2019) ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. *Cell reports*, 29(1), 104.